Boston Scientific to acquire NxThera

Boston Scientific has agreed to take over NxThera and add the company's benign prostatic hyperplasia (BPH) treatment options to its portfolio.

The deal will see a cash payment of USD 306 million made upfront, while up to an additional USD 100 million of potential commercial milestone payments could be made over the next four years.

Boston Scientific already has a minority stake in NxThera, but both parties believe this acquisition could enable more people to benefit from its BPH treatment Rez?m, a minimally invasive therapy.

Bob Paulson, president and chief executive of NxThera, commented: "We are excited to announce this agreement with Boston Scientific.

"Their strong leadership in the field of urology will help drive the Rez?m system forward and ensure that more men have access to this treatment option."

Dave Pierce, senior vice president of Boston Scientific, added that Rez?m is an innovative therapy for men with symptomatic BPH that helps patients with a minimally invasive approach, while at the same time cutting the costs and side-effects associated with taking maintenance medications.

He stated that when compared with other minimally invasive BPH therapies, patients treated with the Rez?m system spend less time seeing the doctor and have longer lasting improvement in their symptoms.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.